DrugPatentWatch Database Preview
DEPO-SUBQ PROVERA 104 Drug Profile
or, see our see our flat-rate plans
When do Depo-subq Provera 104 patents expire, and what generic alternatives are available?
This drug has forty-two patent family members in twenty-nine countries.
The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
Summary for DEPO-SUBQ PROVERA 104
| International Patents: | 42 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 61 |
| Clinical Trials: | 48 |
| Patent Applications: | 4,374 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | DEPO-SUBQ PROVERA 104 at DailyMed |
Pharmacology for DEPO-SUBQ PROVERA 104
| Ingredient-type | Progesterone Congeners |
| Drug Class | Progestin |
Medical Subject Heading (MeSH) Categories for DEPO-SUBQ PROVERA 104
Synonyms for DEPO-SUBQ PROVERA 104
| (1S,2R,8S,10R,11S,14R,15S)-14-ACETYL-2,8,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-14-YL ACETATE |
| (6-alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione |
| (6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl- |
| (6?)-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate |
| (6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl- |
| (6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione |
| (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate |
| (6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate |
| [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate |
| 010M483 |
| 16534-EP2269990A1 |
| 16534-EP2272517A1 |
| 16534-EP2275102A1 |
| 16534-EP2275413A1 |
| 16534-EP2281563A1 |
| 16534-EP2281815A1 |
| 16534-EP2287156A1 |
| 16534-EP2289893A1 |
| 16534-EP2289894A2 |
| 16534-EP2295550A2 |
| 16534-EP2298731A1 |
| 16534-EP2298743A1 |
| 16534-EP2298768A1 |
| 16534-EP2301933A1 |
| 16534-EP2305640A2 |
| 16534-EP2308861A1 |
| 16534-EP2311807A1 |
| 16534-EP2311827A1 |
| 16534-EP2314574A1 |
| 16534-EP2316459A1 |
| 17-Acetoxy-6-alpha-methylprogesterone |
| 17-Acetoxy-6.alpha.-methylprogesterone |
| 17-Acetoxy-6alpha-methylprogesterone |
| 17-alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione |
| 17-alpha-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate |
| 17-alpha-Hydroxy-6-alpha-methylprogesterone acetate |
| 17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate |
| 17.alpha.-Acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione |
| 17.alpha.-Acetoxy-6.alpha.-methylprogesterone |
| 17.alpha.-Hydroxy-6-.alpha.-methylprogesterone acetate |
| 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate |
| 17.alpha.-Hydroxy-6.alpha.-methylprogesterone acetate |
| 17alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione |
| 17alpha-Acetoxy-6alpha-methylprogesterone |
| 17alpha-Hydroxy-6-alpha-methylprogesterone acetate |
| 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate |
| 17alpha-Hydroxy-6alpha-methylprogesterone acetate |
| 4-08-00-02212 (Beilstein Handbook Reference) |
| 6-alpha-Methyl-17-acetoxy progesterone |
| 6-alpha-Methyl-17-alpha-acetoxypregn-4-ene-3,20-dione |
| 6-alpha-Methyl-17-alpha-acetoxyprogesterone |
| 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate |
| 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate |
| 6-alpha-Methyl-4-pregnene-3,20-dion-17-alpha-ol acetate |
| 6.alpha.-Methyl-17-acetoxyprogesterone |
| 6.alpha.-Methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione |
| 6.alpha.-Methyl-17.alpha.-acetoxyprogesterone |
| 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone acetate |
| 6.alpha.-Methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate |
| 6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl- |
| 6alpha-Methyl-17-acetoxy progesterone |
| 6alpha-Methyl-17-acetoxyprogesterone |
| 6alpha-Methyl-17alpha-acetoxypregn-4-ene-3,20-dione |
| 6alpha-Methyl-17alpha-hydroxyprogesterone acetate |
| 6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate |
| 6alpha-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl- |
| 71-58-9 |
| 92480-EP2295416A2 |
| 92480-EP2295426A1 |
| 92480-EP2295427A1 |
| 92480-EP2298748A2 |
| 92480-EP2298768A1 |
| 92480-EP2305642A2 |
| AB00384270_15 |
| AB00384270-14 |
| AB2000663 |
| AC-2174 |
| AC1L1M6L |
| AI3-60127 |
| AK323638 |
| AKOS015894870 |
| Amen |
| AN-14229 |
| Aragest |
| Aragest 5 |
| AS-13981 |
| BDBM50067678 |
| Bio-0669 |
| BRN 2066112 |
| C-21458 |
| C08150 |
| C2QI4IOI2G |
| CAS-71-58-9 |
| CC-30186 |
| CCRIS 371 |
| CHEBI:6716 |
| CHEMBL717 |
| Clinofem |
| Clinovir |
| CM0089 |
| CPD000653524 |
| CS-2583 |
| Cykrina |
| D00951 |
| Depcorlutin |
| Depo-clinovir |
| Depo-Map |
| Depo-Medroxyprogesterone acetate |
| Depo-Prodasone |
| Depo-progestin |
| Depo-Progevera |
| Depo-Promone |
| Depo-Provera |
| Depo-provera (TN) |
| Depo-Provera Contraceptive |
| Depo-ProveraContraceptive |
| Depo-Ralovera |
| Depo-subq provera |
| Depo-subq provera 104 (TN) |
| Depocon |
| Depomedroxyprogesterone acetate |
| Deporone |
| Depot medroxyprogesterone acetate |
| Depot-medroxyprogesterone acetate |
| DP150 |
| DSSTox_CID_5527 |
| DSSTox_GSID_25527 |
| DSSTox_RID_77819 |
| DTXSID0025527 |
| Dugen |
| EINECS 200-757-9 |
| Farlutin |
| Gestapuran |
| HMS2233O07 |
| HMS2235E05 |
| HMS3259O14 |
| HY-B0469 |
| Hysron |
| I028 |
| Indivina |
| KS-00001F8G |
| LS-1607 |
| Lutopolar |
| Lutoral |
| MAP (steroid) |
| Med-Pro |
| medoxyprogesterone |
| Medrosterona |
| Medroxiprogesterone Acetate |
| Medroxyacetate progesterone |
| Medroxyprogesterone (acetate) |
| Medroxyprogesterone 17-acetate |
| Medroxyprogesterone 17-acetate, >=97% (HPLC) |
| Medroxyprogesterone 17-acetate, VETRANAL(TM), analytical standard |
| Medroxyprogesterone 17-acetate;MPA |
| Medroxyprogesterone acetate |
| Medroxyprogesterone acetate (JP17/USP) |
| Medroxyprogesterone acetate [JAN] |
| Medroxyprogesterone acetate [Progestins] |
| Medroxyprogesterone acetate [USP:JAN] |
| Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard |
| Medroxyprogesterone acetate, for performance test, European Pharmacopoeia (EP) Reference Standard |
| Medroxyprogesterone Acetate, pharmaceutical secondary standard; traceable to USP, PhEur abd BP |
| Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard |
| Medroxyprogesterone-17-acetate |
| Medroxyprogesteroneacetate |
| Mepastat |
| Meprate |
| Methylacetoxyprogesterone |
| Metigestrona |
| MLS000069442 |
| MLS001148217 |
| MLS002207115 |
| MolPort-001-794-638 |
| MPA GYM |
| MPA Hexal |
| MPA-beta |
| MPA-Noury |
| MRF-0000023 |
| Nadigest |
| NC00574 |
| NCGC00022037-03 |
| NCGC00022037-04 |
| NCGC00022037-05 |
| NCGC00094713-01 |
| NCGC00257695-01 |
| NCGC00263480-01 |
| Nidaxin |
| NSC 21171 |
| NSC-21171 |
| NSC-26386 |
| NSC21171 |
| NSC26386 |
| ONCO-Provera |
| Opera_ID_1110 |
| Oragest |
| P097000000 |
| Perlutex |
| Perlutex Leo |
| PL000328 |
| Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)- |
| Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate |
| Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)- |
| Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)- |
| Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate |
| Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate (8CI) |
| PREMPHASE (PREMARIN;CYCRIN 14/14) |
| PREMPRO (PREMARIN;CYCRIN) |
| Prodasone |
| Progestalfa |
| Progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate |
| Progesterone, 17-hydroxy-6alpha-methyl-, acetate |
| Progestins |
| Progevera |
| Promone-E |
| Provera |
| Provera (TN) |
| Provera dosepak |
| Proverone |
| PSGAAPLEWMOORI-PEINSRQWSA-N |
| PubChem13062 |
| Ralovera |
| Repromap |
| Repromix |
| s2567 |
| SAM002564220 |
| SCHEMBL4276 |
| Sirprogen |
| SMR000059125 |
| SMR000653524 |
| Sumiferm |
| Supprestral |
| Suprestral |
| Tox21_111319 |
| Tox21_111319_1 |
| Tox21_200141 |
| U 8839 |
| UNII-C2QI4IOI2G |
| Veramix |
| Veraplex |
| ZINC5029557 |
US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | DEPO-SUBQ PROVERA 104 | medroxyprogesterone acetate | INJECTABLE;SUBCUTANEOUS | 021583-001 | Dec 17, 2004 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
International Patents for DEPO-SUBQ PROVERA 104
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Czech Republic | 303872 | ➤ Try a Free Trial |
| Eurasian Patent Organization | 200201208 | ➤ Try a Free Trial |
| Brazil | 0110841 | ➤ Try a Free Trial |
| Czech Republic | 20023750 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0037 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
